Yousif H Matloub

Learn More
BACKGROUND Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or(More)
BACKGROUND Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. To(More)
The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT triples (ITT) (MTX,(More)
1Division of Hematology-Oncology, Doernbecher Children’s Hospital/Oregon Health & Science University, Portland; 2Division of Hematology-Oncology, Rainbow Babies & Children’s Hospital, Case Western(More)